
Dr Armstrong on Androgen Receptor Inhibitors for Prostate Cancer
Here, Andrew J. Armstrong, MD, MSc, medical oncologist at Duke Cancer Institute, discusses the role of androgen receptor pathway inhibitors (ARPIs) in prostate cancer. Enzalutamide (Xtandi), much like its counterparts apalutamide (Erleada), abiraterone ( …